HighTower Advisors’s Charles River Laboratories CRL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $857K | Buy |
3,781
+203
| +6% | +$36.1K | ﹤0.01% | 2343 |
|
|
2026
Q1 | $617K | Sell |
3,578
-407
| -10% | -$75.5K | ﹤0.01% | 2548 |
|
|
2025
Q4 | $795K | Sell |
3,985
-18
| -0.4% | -$3.27K | ﹤0.01% | 2285 |
|
|
2025
Q3 | $626K | Sell |
4,003
-671
| -14% | -$107K | ﹤0.01% | 2436 |
|
|
2025
Q2 | $709K | Sell |
4,674
-1,291
| -22% | -$172K | ﹤0.01% | 2249 |
|
|
2025
Q1 | $898K | Sell |
5,965
-748
| -11% | -$125K | ﹤0.01% | 2034 |
|
|
2024
Q4 | $1.24M | Sell |
6,713
-3,698
| -36% | -$712K | ﹤0.01% | 1822 |
|
|
2024
Q3 | $2.05M | Sell |
10,411
-619
| -6% | -$129K | ﹤0.01% | 1510 |
|
|
2024
Q2 | $2.27M | Sell |
11,030
-1,017
| -8% | -$230K | ﹤0.01% | 1376 |
|
|
2024
Q1 | $3.27M | Buy |
12,047
+820
| +7% | +$196K | 0.01% | 1162 |
|
|
2023
Q4 | $2.65M | Sell |
11,227
-2,752
| -20% | -$541K | ﹤0.01% | 1286 |
|
|
2023
Q3 | $2.76M | Sell |
13,979
-340
| -2% | -$69.8K | 0.01% | 1209 |
|
|
2023
Q2 | $3.01M | Sell |
14,319
-4,173
| -23% | -$830K | 0.01% | 1133 |
|
|
2023
Q1 | $3.72M | Sell |
18,492
-15,151
| -45% | -$3.43M | 0.01% | 986 |
|
|
2022
Q4 | $7.35M | Buy |
33,643
+5,709
| +20% | +$1.25M | 0.02% | 702 |
|
|
2022
Q3 | $5.53M | Buy |
27,934
+6,949
| +33% | +$1.5M | 0.01% | 761 |
|
|
2022
Q2 | $4.48M | Sell |
20,985
-9,375
| -31% | -$2.29M | 0.01% | 872 |
|
|
2022
Q1 | $8.63M | Sell |
30,360
-498
| -2% | -$154K | 0.02% | 678 |
|
|
2021
Q4 | $11.7M | Buy |
30,858
+11,773
| +62% | +$4.57M | 0.03% | 549 |
|
|
2021
Q3 | $7.86M | Buy |
19,085
+112
| +0.6% | +$46.5K | 0.02% | 647 |
|
|
2021
Q2 | $7.02M | Buy |
18,973
+700
| +4% | +$234K | 0.02% | 664 |
|
|
2021
Q1 | $5.29M | Buy |
18,273
+1,638
| +10% | +$455K | 0.02% | 716 |
|
|
2020
Q4 | $4.13M | Buy |
16,635
+86
| +0.5% | +$20.5K | 0.02% | 646 |
|
|
2020
Q3 | $3.75M | Buy |
16,549
+446
| +3% | +$92.6K | 0.02% | 651 |
|
|
2020
Q2 | $2.81M | Buy |
16,103
+1,307
| +9% | +$209K | 0.02% | 692 |
|
|
2020
Q1 | $1.88M | Buy |
14,796
+114
| +0.8% | +$17.1K | 0.01% | 768 |
|
|
2019
Q4 | $2.25M | Buy |
14,682
+357
| +2% | +$49.4K | 0.01% | 813 |
|
|
2019
Q3 | $1.9M | Buy |
14,325
+331
| +2% | +$44.4K | 0.01% | 902 |
|
|
2019
Q2 | $1.99M | Buy |
13,994
+423
| +3% | +$57.4K | 0.01% | 904 |
|
|
2019
Q1 | $1.97M | Buy |
13,571
+665
| +5% | +$87.4K | 0.01% | 858 |
|
|
2018
Q4 | $1.46M | Buy |
12,906
+6,725
| +109% | +$842K | 0.01% | 892 |
|
|
2018
Q3 | $831K | Buy |
6,181
+881
| +17% | +$109K | 0.01% | 1214 |
|
|
2018
Q2 | $590K | Sell |
5,300
-4,072
| -43% | -$440K | ﹤0.01% | 1371 |
|
|
2018
Q1 | $987K | Buy |
9,372
+5,020
| +115% | +$541K | 0.01% | 1083 |
|
|
2017
Q4 | $478K | Sell |
4,352
-1,088
| -20% | -$118K | ﹤0.01% | 1465 |
|
|
2017
Q3 | $586K | Buy |
+5,440
| New | +$559K | 0.01% | 1357 |
|
|
2016
Q3 | – | Sell |
-8,632
| Closed | -$714K | – | 1888 |
|
|
2016
Q2 | $714K | Buy |
+8,632
| New | +$711K | 0.01% | 1011 |
|
Other funds holding CRL
AI
HighTower Advisors's CRL Position: Q2 2026 in Review
HighTower Advisors increased its Charles River Laboratories (CRL) stake by 5.7% in Q2 2026, buying an estimated $36.1K and bringing the position to 3,781 shares worth $857K. The position accounts for ﹤0.01% of the portfolio, ranked #2343.
HighTower Advisors first reported a position in CRL in Q2 2016 and has held it in 37 quarters since. The position peaked at $11.7M in Q4 2021. 569 funds tracked by Wall St. Rank hold CRL as of Q2 2026.
- HighTower Advisors held 3,781 shares of Charles River Laboratories worth $857K as of Q2 2026.
- HighTower Advisors bought 203 Charles River Laboratories shares in Q2 2026, an estimated $36.1K.
- Charles River Laboratories made up ﹤0.01% of HighTower Advisors's portfolio in Q2 2026, its #2343 holding.
- HighTower Advisors first reported a position in Charles River Laboratories in Q2 2016 and has held it in 37 quarters since.
- HighTower Advisors's Charles River Laboratories position peaked at $11.7M in Q4 2021.
- 569 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2026.
Based on HighTower Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.